Figure 3 | Scientific Reports

Figure 3

From: Predicting treatment outcomes of intravitreal brolucizumab for polypoidal choroidal vasculopathy through noninvasive assessment of polypoidal lesion blood flow with optical coherence tomography angiography

Figure 3

Changes in average central choroidal thickness in eyes with polypoidal choroidal vasculopathy treated with 3 monthly intravitreal injections of brolucizumab followed by a treat-and-extend regimen with intravitreal brolucizumab. Central choroidal thickness (CCT) was significantly reduced and the reduction was maintained during the 1-year study period in both the group showing disappearance of blood flow signals and that without such findings (**P < 0.01). The CCT reductions did not differ significantly between the two groups.

Back to article page